Your browser is no longer supported. Please, upgrade your browser.
Settings
ALNY Alnylam Pharmaceuticals, Inc. daily Stock Chart
ALNY [NASD]
Alnylam Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-7.88 Insider Own0.40% Shs Outstand105.21M Perf Week0.42%
Market Cap7.55B Forward P/E- EPS next Y-7.27 Insider Trans-13.28% Shs Float105.21M Perf Month5.73%
Income-802.20M PEG- EPS next Q-1.85 Inst Own92.30% Short Float5.13% Perf Quarter-14.70%
Sales86.30M P/S87.53 EPS this Y-39.80% Inst Trans4.79% Short Ratio5.52 Perf Half Y9.10%
Book/sh14.68 P/B4.89 EPS next Y10.90% ROA-45.50% Target Price121.56 Perf Year-30.08%
Cash/sh11.83 P/C6.07 EPS next 5Y46.09% ROE-53.90% 52W Range60.27 - 124.21 Perf YTD-1.52%
Dividend- P/FCF- EPS past 5Y-39.20% ROI-59.70% 52W High-42.20% Beta2.51
Dividend %- Quick Ratio9.10 Sales past 5Y9.70% Gross Margin94.00% 52W Low19.13% ATR2.43
Employees1065 Current Ratio9.30 Sales Q/Q52.10% Oper. Margin- RSI (14)46.76 Volatility3.28% 3.24%
OptionableYes Debt/Eq0.02 EPS Q/Q-21.50% Profit Margin- Rel Volume0.49 Prev Close74.37
ShortableYes LT Debt/Eq0.02 EarningsJul 31 BMO Payout- Avg Volume976.77K Price71.80
Recom2.10 SMA202.24% SMA50-4.19% SMA200-11.27% Volume479,560 Change-3.46%
May-23-19Resumed Goldman Neutral $80
Apr-12-19Initiated Evercore ISI Outperform
Mar-06-19Upgrade Evercore ISI In-line → Outperform
Mar-05-19Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-23-19Initiated UBS Neutral $87
Oct-01-18Initiated Cantor Fitzgerald Overweight $135
Aug-13-18Reiterated Stifel Buy $125 → $123
Aug-07-18Upgrade Stifel Hold → Buy $95 → $125
May-04-18Reiterated Stifel Hold $107 → $95
Mar-28-18Initiated Evercore ISI In-line
Mar-26-18Reiterated JMP Securities Mkt Outperform $169 → $207
Feb-16-18Reiterated B. Riley FBR, Inc. Buy $205 → $200
Jan-08-18Reiterated B. Riley FBR, Inc. Buy $220 → $205
Nov-09-17Upgrade JP Morgan Neutral → Overweight
Nov-08-17Reiterated Barclays Overweight $127 → $158
Nov-08-17Reiterated B. Riley FBR, Inc. Buy $240 → $220
Nov-03-17Reiterated Needham Buy $125 → $152
Nov-02-17Reiterated B. Riley FBR, Inc. Buy $150 → $240
Oct-30-17Initiated FBR & Co. Buy $150
Oct-02-17Upgrade Goldman Neutral → Buy
Jun-24-19 07:00AM  Alnylam Presents New ONPATTRO® (patisiran) Results at the 2019 Peripheral Nerve Society Annual Meeting Business Wire
Jun-21-19 07:00AM  Alnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Delivery Business Wire
Jun-19-19 08:09PM  Heres What Hedge Funds Think About Alnylam Pharmaceuticals, Inc. (ALNY) Insider Monkey
Jun-18-19 09:58AM  Alnylam Completes Enrollment in Phase III Study of Lumasiran Zacks
08:00AM  Alnylam Announces Approval in Japan of ONPATTRO® for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy Business Wire
Jun-17-19 09:12AM  Regeneron (REGN) Presents Positive Data on Lymphoma Candidate Zacks
07:00AM  Alnylam Completes Enrollment for ILLUMINATE-A Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1) Business Wire
Jun-14-19 02:50PM  Why Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Is A Financially Healthy Company Simply Wall St.
Jun-13-19 12:03PM  Boston-area biopharm firm has big plans in Philadelphia American City Business Journals
08:00AM  Alnylam to Report New Clinical Results for ONPATTRO® (patisiran) at Peripheral Nerve Society (PNS) Annual Meeting and the 5th Congress of the European Academy of Neurology (EAN) Business Wire
Jun-06-19 03:28PM  Alnylam Completes Rolling NDA Submission to FDA for Givosiran Zacks
Jun-05-19 07:00AM  Alnylam Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Givosiran for the Treatment of Acute Hepatic Porphyria Business Wire
Jun-03-19 04:48PM  Alnylam Initiates Phase I Study on Hypertension Candidate Zacks
May-31-19 09:31AM  Why Is Alnylam (ALNY) Down 16.8% Since Last Earnings Report? Zacks
07:00AM  Alnylam Doses First Patient in Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension Business Wire
May-30-19 04:00PM  Alnylam to Webcast Presentations at Upcoming June Investor Conferences Business Wire
May-29-19 10:52AM  BioMarin Announces Data on Hemophilia Candidate, Shares Fall Zacks
08:00AM  Alnylam Announces New Leadership Appointments Business Wire
May-20-19 12:04PM  Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock InvestorPlace
May-09-19 07:46AM  These 3 revolutionary genomics companies are changing lives for patients and investors MarketWatch
07:00AM  Alnylam to Webcast Presentation at Bank of America Merrill Lynch Health Care Conference 2019 Business Wire
May-08-19 08:03AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
May-07-19 08:21PM  Can Pfizer Leap Over the Competition With This Potential Blockbuster? Motley Fool
May-06-19 04:14PM  How Dow Jones' Pfizer Could Take On New Drugs From 2 Biotech Stocks Investor's Business Daily
10:04AM  Alnylam Pharmaceuticals Continues Onpattro Launch With More to Come Motley Fool
May-03-19 03:23PM  Edited Transcript of ALNY earnings conference call or presentation 1-May-19 12:30pm GMT Thomson Reuters StreetEvents -6.36%
01:49PM  Alnylam Pharmaceuticals Put Buyers Take Profits During Slide Schaeffer's Investment Research
May-02-19 06:43PM  Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks GuruFocus.com
04:57PM  Regeneron (REGN) to Report Q1 Earnings: What's in Store? Zacks
10:00AM  Alnylam (ALNY) Reports Narrower-Than-Expected Loss in Q1 Zacks
09:16AM  Can Alnylam Pharmaceuticals Stock Start Climbing Again? Motley Fool
May-01-19 04:20PM  Alnylam Pharmaceuticals Inc (ALNY) Q1 2019 Earnings Call Transcript Motley Fool -7.06%
01:16PM  Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates Zacks
08:08AM  Alnylam: 1Q Earnings Snapshot Associated Press
08:00AM  Alnylam Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Period Activity Business Wire
06:30AM  Alnylam Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Apr-30-19 04:00PM  Alnylam Highlights Progress on Global Market Access for ONPATTRO (patisiran) Business Wire
Apr-26-19 11:11AM  Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus Zacks
Apr-23-19 04:00PM  Alnylam to Webcast Conference Call Discussing First Quarter 2019 Financial Results Business Wire +5.11%
Apr-22-19 01:54PM  This Is Why You Shouldnt Count Regeneron Stock Out InvestorPlace
Apr-19-19 10:41AM  Here is What Hedge Funds Think About Alnylam Pharmaceuticals, Inc. (ALNY) Insider Monkey
Apr-16-19 07:13PM  Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran Zacks
07:27AM  Is Alnylam Pharmaceuticals a Buy Now? Motley Fool
Apr-15-19 04:49PM  Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran Zacks
07:00AM  Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study Business Wire
Apr-12-19 06:01PM  Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria Business Wire
07:23AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Apr-11-19 09:27AM  4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics Zacks
Apr-10-19 09:20AM  Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More Zacks
Apr-09-19 09:03AM  Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics Zacks
Apr-08-19 01:55PM  Regeneron, Alnylam Strike $1B Collaboration For RNAi-based Therapeutics Benzinga
11:13AM  Regeneron forays into gene-silencing therapies with Alnylam tie-up Reuters
09:10AM  Alnylam trades partner Sanofi for Regeneron in $800M deal American City Business Journals
08:50AM  What Do Analysts Think About Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Earnings Trajectory? Simply Wall St.
07:11AM  Alnylam, Regeneron to partner for RNAi treatments Reuters
07:00AM  Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases PR Newswire
07:00AM  Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases Business Wire
01:00AM  Alnylam and Sanofi Conclude Research and Option Phase of 2014 RNAi Therapeutics Collaboration Business Wire
Mar-30-19 11:31AM  2 Biotechs With Big Dates in April Motley Fool
Mar-27-19 07:00AM  Alnylam to Present Givosiran Phase 3 Data at the European Association for the Study of the Liver (EASL) International Liver Congress Business Wire
Mar-20-19 07:07AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Mar-18-19 06:51PM  Alnylam's (ALNY) Impressive Pipeline Drives Share Price Zacks
Mar-12-19 09:59AM  Alnylam Files Application for Hypertension Candidate in UK Zacks
Mar-11-19 07:00AM  Alnylam Submits CTA Application for ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension in High Unmet Need Settings Business Wire +5.50%
Mar-09-19 08:31AM  Why Is Alnylam (ALNY) Up 3.1% Since Last Earnings Report? Zacks
Mar-07-19 04:00PM  Alnylam to Webcast Presentation at Cowen & Company 39th Annual Health Care Conference Business Wire
09:00AM  Alnylam Stock Down Despite Positive Phase III Givosiran Data Zacks
Mar-06-19 04:10PM  Could This Biotech Sacrifice A Buy Point On Drug Safety Questions? Investor's Business Daily
11:06AM  Side effects of Alnylam's gene-silencing drug raise concerns, shares slip Reuters
09:12AM  Alnylam Pharmaceuticals stock down 7.5% after announcing results of Phase 3 givosiran trial MarketWatch
08:20AM  After trial success, Alnylam plans to seek FDA approval for 2nd drug American City Business Journals
07:08AM  Alnylam's gene-silencing drug meets main goal in late-stage study Reuters
07:00AM  Alnylam Reports Positive Topline Results from ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria Business Wire
Mar-04-19 09:19AM  Can This Biotech Puppy Run With the Big Dogs? Motley Fool
Feb-28-19 09:50AM  Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus Zacks
07:00AM  Alnylam Announces Recipients of First Annual Advocacy for Impact Grants Program Business Wire
Feb-25-19 06:43AM  FDA panel says Karyopharm's cancer drug shows 'significant toxicity' American City Business Journals
Feb-14-19 06:48PM  Alnylam Pharmaceuticals Inc (ALNY) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
12:01PM  Is Moderna a Buy? Motley Fool
Feb-12-19 10:04AM  Alnylam Pharmaceuticals Is Launched and Ready for More Motley Fool
08:10AM  Detailed Research: Economic Perspectives on DXC Technology, AMC Networks, SunCoke Energy Partners, Alnylam Pharmaceuticals, Amtech, and Diamond Hill Investment Group What Drives Growth in Today's Competitive Landscape GlobeNewswire
Feb-11-19 11:14AM  Edited Transcript of ALNY earnings conference call or presentation 7-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Feb-08-19 09:17AM  The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs Benzinga
07:47AM  Alnylam's (ALNY) Q4 Earnings and Revenues Beat Estimates Zacks
Feb-07-19 11:15PM  Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:15PM  Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates Zacks
05:23PM  Alnylam: 4Q Earnings Snapshot Associated Press
04:00PM  Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity Business Wire
Feb-06-19 05:00PM  Alnylam Announces Publication of Phase 1 Givosiran Data in The New England Journal of Medicine Business Wire
Feb-04-19 04:00PM  Alnylam to Webcast Presentations at Upcoming February Investor Conferences Business Wire
Jan-31-19 04:00PM  Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2018 Financial Results Business Wire
07:55AM  Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sarepta Therapeutics ACCESSWIRE
Jan-24-19 10:51AM  The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio Zacks
Jan-23-19 10:48AM  5 Best Biotech Bets Likely to Outperform Estimates in Q4 Zacks
09:12AM  Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs Zacks
Jan-22-19 07:58AM  Alnylam & Medison Partner to Market RNAi Products in Israel Zacks
Jan-21-19 03:00AM  Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel Business Wire
Jan-16-19 07:30AM  New Research Coverage Highlights Gentex, Tenneco, Mercury General, MGM Resorts International, ResMed, and Alnylam Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Jan-15-19 08:00AM  Pfizer Gets FDA's Priority Review for Rare Disease Candidate Zacks
Jan-14-19 09:13PM  Alnylam Pharmaceuticals Prices Public Offering of Common Stock Business Wire -5.72%
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The company's development programs include Vutrisiran, an investigational RNAi therapeutic targeting transthyretin that is in Phase III trials for the treatment of transthyretin-mediated amyloidosis; Givosiran that is in Phase III trials to treat acute hepatic porphyrias; and Lumasiran, an investigational RNAi therapeutic, which is in Phase III clinical trials for glycolate oxidase to treat primary hyperoxaluria type 1. It is also developing Inclisiran, an investigational RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9 that is in Phase III clinical trials for the treatment of hypercholesterolemia; and Fitusiran, an investigational RNAi therapeutic that is in Phase III clinical trials for treating hemophilia A and B with or without inhibitors. In addition, the company engages in the development of Cemdisiran for complement-mediated diseases; ALN-AAT02 to treat alpha-1 anti-trypsin deficiency-associated liver disease; ALN-HBV02 for treating chronic hepatitis B virus infection; and other earlier-stage programs. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARAGANORE JOHNChief Executive OfficerMay 15Option Exercise16.4349,457812,579239,450May 17 04:07 PM
MARAGANORE JOHNChief Executive OfficerMay 15Sale70.0049,4573,461,990189,993May 17 04:07 PM
SHARP PHILIP ADirectorApr 15Option Exercise22.0915,000331,350250,633Apr 17 04:05 PM
SHARP PHILIP ADirectorApr 15Sale88.2315,0001,323,442235,633Apr 17 04:05 PM
MARAGANORE JOHNChief Executive OfficerNov 21Option Exercise21.3598,6362,105,879249,933Nov 26 04:11 PM
Greenstreet YvonneEVP, Chief Operating OfficerAug 30Sale120.002,500300,0001,916Sep 04 04:15 PM
MARAGANORE JOHNChief Executive OfficerJul 25Option Exercise21.3550,0001,067,500201,297Jul 27 04:07 PM
MARAGANORE JOHNChief Executive OfficerJul 25Sale105.3950,0005,269,457151,297Jul 27 04:07 PM